[Pubmed] Treatment strategies and treatment-related adverse events in MG according to the age of onset
Posté : 26 mars 2024 11:00
Front Neurol. 2024 Mar 11;15:1277420. doi: 10.3389/fneur.2024.1277420. eCollection 2024.
ABSTRACT
INTRODUCTION: Early-onset (EOMG) and late-onset (LOMG) are distinct groups of MG patients. It is unclear if treatment strategies and treatment-related adverse events may differ according to the age of MG onset.
METHODS: This single-center retrospective study includes all MG patients followed at a tertiary center since 2007. We reviewed the electronic clinical records.
RESULTS: In total, 212 patients were identified, 142 (67.0%) females, with a median disease duration of 10 years. The median age of symptom onset was 42.0 (26.0-64.5) years, with 130 (61.3%) EOMG cases and 82 (38.7%) LOMG. EOMG were more frequently female, had longer disease duration and often more generalized MG (p < 0.001). Comorbidities were significantly more frequent in LOMG (67.1%) compared to EOMG (53.1%) (p = 0.002). Steroid-related adverse effects motivating the switch to steroid-sparing agents (82.0%) were different between groups, with hypertension, hypercholesterolemia, diabetes mellitus and malignancies being more common in LOMG. At the same time, osteoporosis and dyspepsia were more frequent in EOMG (p < 0.001). The most common first-line choice was azathioprine (45.8%), and rituximab was used in 4 patients (1.9%).
CONCLUSION: Our study shows that treatment modalities are similar between EOMG and LOMG, while steroid-related adverse events appear to be distinct.
PMID:38529037 | PMC:PMC10961456 | DOI:10.3389/fneur.2024.1277420
Source: https://pubmed.ncbi.nlm.nih.gov/3852903 ... t9+e462414